The antiretrovirals in pregnancy registry: A fifteenth anniversary celebration

Obstetrical and Gynecological Survey

Volumn 62, Issue 2, 2007, Pages 137-148

  Tilson, Hugh H ^a   Doi, Peggy A ^b   Covington, Deborah L ^b   Parker, Artist ^c   Shields, Kristine ^d   White, Alice ^e  

^a IL   (United States)

^b Kendle International Inc   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ADEFOVIR DIPIVOXIL; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ENTECAVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

BIRTH DEFECT; DISEASE REGISTRY; DRUG MONITORING; DRUG SAFETY; HUMAN; INCIDENCE; PERINATAL DRUG EXPOSURE; PREGNANCY; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; TERATOGENICITY;

ANTI-RETROVIRAL AGENTS; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REGISTRIES;

EID: 33846421606     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ogx.0000253377.14647.80     Document Type: Review

References (39)

1. Pregnancy and Medications. The National Women's Health Information Center. US Department of Health and Human Services, Office of Women's Health. Available at: http://www.4woman.gov/faq/pregmed.htm. Accessed December 2006.
2. Andrews EB, Yankaskas BC, Cordero JF, et al. Acyclovir in pregnancy registry: six years' experience. The acyclovir in Pregnancy Registry Advisory Committee. Obstet Gynecol 1992;79:7-13.
3. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the International Acyclovir Pregnancy Registry, 1984-1999. Birth Defects Res A Clin Mol Teratol 2004;70:201-207.
4. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR 2002; 51(No. RR-6). Available at: URL http://www.cdc.gov/STD/treatment/. Accessed December 2006.
5. White A, Andrews E, Eldridge R, et al. Birth outcomes following zidovudine therapy in pregnant women. MMWR 1994;43:409, 415-416.
6. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR 1998;47 (No. RR-2), 1-30. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ 00053202.htm. Accessed December 2006.
7. Centers for Disease Control and Prevention. Metropolitan Atlanta Congenital Defects Program. Surveillance procedure manual and guide to computerized anomaly record. Atlanta, GA: US Department of Health and Human Services, Public Health Service; 1998. To obtain a copy of the MACDP Procedure Manual or Defect Code, send an email request to macdp@cdc.gov.
8. Correa-Villasenor A, Cragan J, Kucik J, et al. The Metropolitan Atlanta Congenital Defects Program: 35 years of birth defects surveillance at the Centers for Disease Control and Prevention. Birth Defects Res A Clin Mol Teratol 2003;67:617-624.
9. Covington DL, Tilson H, Elder J, et al. APR Steering Committee. Assessing teratogenicity of antiretroviral drugs: monitoring and analysis plan of the Antiretroviral Pregnancy Registry. Pharmacoepidemiol Drug Saf 2004;13:537-545.
10. Department of Health and Human Services. Protecting personal health information in research: understanding the HIPAA Privacy Rule. NIH Publication Number 03-5388;2003. Available at http://privacyruleandresearch.nih.gov. Accessed December 2006.
11. Food and Drug Administration (FDA). Guidance for industry: establishing pregnancy exposure registries. Rockville, MD: US Department of Health and Human Services, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research; 2002. Available at http://www.fda.gov/cber/gdlns/ pregnancy.pdf. Accessed December 2006.
12. Response from Antiretroviral Pregnancy Registry: draft FDA guidance for industry on establishing pregnancy registries. Docket number: 99D-1541, December 1999.
13. Centers for Disease Control and Prevention. Concepts and strategies to actively monitor the risks of medications in pregnancy: enhancing post-marketing surveillance. Workshop Summary, November 29-30, 2000.
14. Covington DL, Doi PA, Tilson H. APR Steering Committee. Antiretroviral Pregnancy Registry conforms with FDA Guidelines for Pregnancy Exposure Registries. Pharmacoepidemiol Drug Saf 2003;12 (Suppl 1):S22.
15. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2006. Wilmington, NC: Registry Coordinating Center; 2006. Available at http://www.apregistry.com. Accessed December 2006.
16. Scheuerle A, Covington DL. Clinical review procedures for the Antiretroviral Pregnancy Registry. Pharmacoepidemiol Drug Saf 2004;13:529-536.
17. Scheuerle A, Tilson H. Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry. Pharmacoepidemiol Drug Saf 2002;11:465-475.
18. Watts DH, Covington DL, Beckerman K, et al. Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Obstet Gynecol 2004;191:985-992.
19. White A, Eldridge R, Andrews E. Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry. Acta Paediatr Suppl 1997;421:86-88.
20. Beckerman K, Covington DL, Garcia P, et al. Association between antiretroviral therapy during pregnancy and prematurity/low birth weight. Oral presentation at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11, 2004.
21. Beckerman K, Covington DL, Watts H, et al. APR Steering Committee. Risk of birth defects associated with antiretroviral exposure during pregnancy. Oral presentation at the 24th Annual Society for Maternal-Fetal Medicine Scientific Meeting, New Orleans, LA, February 2-7, 2004. Am J Obstet Gynecol 2004;189(Suppl):S56.
22. Beckerman K, Watts H, Covington DL, et al. Assessing the risk of central nervous birth defects associated with antiretroviral exposure during pregnancy. Poster presentation at the 13th Annual Conference on Retroviruses & Opportunities Infections, Denver, CO, February 2006.
23. Clax P, Covington DL. Antiretroviral Pregnancy Registry-a multi-company pregnancy registry. Oral presentation at the 7th Forum on Patient Registries, CBI, Philadelphia, September 2005.
24. Covington DL, Doi PA, Baylor M, et al. The new generation pregnancy exposure registries. Pharmacoepidemiol Drug saf 2004;13(Suppl 1):S43-S44.
25. Covington DL, Dominguez K, Kucik J, et al. Risk of birth defects associated with antiretroviral exposure during pregnancy. Poster presentation at the Treatment & Management of HIV Infection in United States Conference, Atlanta, GA, September 15-18, 2005.
26. Covington DL, Tilson H, Elder J, et al. APR Steering Committee. Assessing teratogenicity of antiretroviral drugs: monitoring and analysis plan of the Antiretroviral Pregnancy Registry. Pharmacoepidemiol Drug Saf 2002;11(Suppl 1):S137.
27. Covington DL. Multi-drug/multi-company models - the Antiretroviral Pregnancy Registry experience. Oral presentation at the DIA Workshop, Pregnancy Exposure Registries: evaluating the teratogenic potential of pharmaceutical products used at clinical doses, Washington, DC, May 24-25, 2004.
28. Dominguez K, Covington DL. Prospective monitoring: the Antiretroviral Pregnancy Registry. Oral presentation at the Symposium on Monitoring the Effects of Medication Use During Pregnancy and Lactation. National Center on Birth Defects and Developmental Disabilities, CDC, Atlanta, GA, December 13 2004.
29. Garcia P, Watts DH, Fox HE, et al. Assessing the teratogenic potential of antiretroviral drugs: data from the Antiretroviral Pregnancy Registry (APR). Poster presentation at the 7th Conference on Retroviruses and Opportunistic Infections, January 2000.
30. Garcia PM, Beckerman K, Watts DH, et al. Assessing the teratogenic potential of antiretroviral drugs: data from the Antiretroviral Pregnancy Registry (APR). Poster presentation at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 2001.
31. Garcia PM, Covington DL, Watts DH, et al. Antiretroviral therapy in pregnancy: exposure patterns over time and the prevalence of birth defects. Poster presentation at the 14th International AIDS Conference, Barcelona, Spain, July 2002.
32. Garcia PM, Watts DH, Fox HE, et al. Assessing the teratogenic potential of antiretroviral drugs: data from the Antiretroviral Pregnancy Registry (APR). Poster presentation at the Society of Maternal and Fetal Medicine, January 2001.
33. Ross B, Beckerman K, Doi P, et al. The Antiretroviral Pregnancy Registry: ten years of progress and ten years of data. Poster presentation at the 54th Annual Clinical Meeting of the American College of Obstetricians & Gynecologists, Washington, DC, May 2006.
34. Scheuerle A, Watts H, Covington DL, et al. Assessing a potential signal in the Antiretroviral Pregnancy Registry. Poster presentation at the National Birth Defects Prevention Network Annual Meeting, Arlington, VA, January 2006.
35. Schwamlein C. Antiretroviral Pregnancy Registry - example of a long-standing registry. Oral presentation at the 2nd Annual CBI Patient Registries Conference, Orlando, Florida, January 2002.
36. Shields KE, Wiholm BE, Hostelley LS, et al. Monitoring outcomes of pregnancy following drug exposure: a company-based pregnancy registry program. Drug Saf 2004;27:353-367.
37. Tilson H, Doi PA, Parker A, et al. The Antiretroviral Pregnancy Registry: ten years of progress. Oral presentation at the 19th International Conference on PharmacoEpidemiology, Philadelphia, PA, August 2003. Pharmacoepidemiol Drug Saf 2003;12(Suppl 1):S135.
38. Tilson H, Covington DL, Watts DH. Effective use of supplemental data in pregnancy exposure registries. Presented at the 22nd International Conference on PharmacoEpidemiology, Lisbon, Portugal, August 2006.
39. Roberts S, Covington D, Doi P. Pregnancy exposure registries: streamlining regulatory requirements to increase enrollment. Presented at the 21st International Conference on Pharmacoepidemiology, Nashville, TN, August 2005.